Relmada Therapeutics ( ($RLMD) ) has shared an announcement. On September 17, 2025, Relmada Therapeutics updated its corporate presentation, ...

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase 3 clinical trial in gMG is currently ...

Apple executives stick to one big idea per slide to make product messages stick. Here's how to embrace this fundamental presentation rule.

Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profileKT-621 ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of ...

In the wake of several significant departures from its design team, Apple underscored its dedication to design during its ...

Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic ...

Imperative Care today announced positive efficacy and safety results from its pivotal SYMPHONY-PE thrombectomy system study.

Phillips 66 is transforming its refining business through cost reductions and strategic portfolio shifts, aiming to become a ...

Protagonist Therapeutics (PTGX) announced new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies which assessed the superiority of icotrokinra, ...

Soleno Therapeutics faces scrutiny over Vykat safety after a patient death. Click here to find out why I rate SLNO a Hold.